O 304

Drug Profile

O 304

Alternative Names: O304

Latest Information Update: 08 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Betagenon
  • Class Cardiovascular therapies; Obesity therapies; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cancer; Metabolic disorders; Peripheral arterial disorders; Type 2 diabetes mellitus

Highest Development Phases

  • Phase II Type 2 diabetes mellitus
  • Phase I Metabolic disorders; Peripheral arterial disorders
  • Preclinical Cancer

Most Recent Events

  • 08 Aug 2017 O 304 is available for licensing as of 08 Aug 2017. http://betagenon.se (Betagenon website, August 2017)
  • 27 Aug 2016 Phase-II clinical trials in Type-2 diabetes mellitus in Sweden (PO) (9202250; EudraCT2016-002183-13)
  • 02 Feb 2015 Pharmacodynamics data from a preclinical study in metabolic disorders released by Betagenon
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top